Production (Stage)
Ernexa Therapeutics Inc.
ERNA
$2.29
-$0.08-3.38%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -42.42% | 78.35% | -381.17% | 16.82% | -8.03% |
| Total Depreciation and Amortization | 1.47% | -84.92% | -21.97% | 6.84% | 12.47% |
| Total Amortization of Deferred Charges | -- | 153.13% | 159.28% | 6.52% | 77.29% |
| Total Other Non-Cash Items | 1,167.25% | -97.90% | 4,603.86% | -50.11% | 219.86% |
| Change in Net Operating Assets | 115.85% | 56.54% | -287.27% | 78.78% | 109.40% |
| Cash from Operations | 41.75% | 43.60% | -178.22% | 39.71% | 19.61% |
| Capital Expenditure | -- | 100.00% | 92.37% | -146.53% | -431.58% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -100.00% | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | 100.00% | 92.37% | -156.70% | -410.53% |
| Total Debt Issued | -- | -100.00% | -- | -100.00% | -84.87% |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -99.65% | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | 100.00% | -- | -- |
| Other Financing Activities | -- | -- | 100.00% | 30.00% | 73.68% |
| Cash from Financing | 123.17% | -74.02% | 17,768.18% | -101.59% | -82.02% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 107.46% | -4.88% | 4.47% | -2.89% | -181.32% |